(E)-5-[1-[3-[4-[(E)-5-(3,4-dihydroxyphenyl)-3-oxopent-4-enyl]triazol-1-yl]-2,2-bis[[4-[(E)-5-(3,4-dihydroxyphenyl)-3-oxopent-4-enyl]triazol-1-yl]methyl]propyl]triazol-4-yl]-1-(4-hydroxy-3-methylphenyl)pent-1-en-3-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-5-[1-[3-[4-[(E)-5-(3,4-dihydroxyphenyl)-3-oxopent-4-enyl]triazol-1-yl]-2,2-bis[[4-[(E)-5-(3,4-dihydroxyphenyl)-3-oxopent-4-enyl]triazol-1-yl]methyl]propyl]triazol-4-yl]-1-(4-hydroxy-3-methylphenyl)pent-1-en-3-one
• 化学式: C₅₈H₅₈N₁₂O₁₁
• 分子量: 1099.2
• InChiKey: NZKVNSGUVPBLKT-CCMUROTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  81
• 可旋转键数：
  28
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  333
• 氢给体数：
  7
• 氢受体数：
  19

文献信息

• TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE
  申请人：Mayer-Barber Katrin

  公开号：US20140171445A1

  公开（公告）日：2014-06-19

  The invention provides a method of enhancing the efficacy of antibiotic treatment of tuberculosis, trypanosomiasis, leprosy, and leishmaniasis involving co-administering to a mammal undergoing antibiotic treatment therapeutically effective amounts of a first compound that is an inhibitor of 5-lipoxygenase and optionally a second compound that is a product of the cyclooxygenase pathways. The invention also provides a pharmaceutical composition comprising an antibiotic, an inhibitor of 5-lipoxygenase, and a product of the cyclooxygenase pathways.